Summary of recommendations for newly diagnosed NLPHL
| Stage . | Treatment . |
|---|---|
| Stage IA | 30-Gy IS-RT alone |
| Early stages except for stage IA | 2 × (R-)ABVD + 20-Gy IS-RT |
| Intermediate stages | 4 × (R-)ABVD + 30-Gy IF-RT |
| Advanced stages | 6 × R-CHOP ± localized RT at 30 Gy |
| Stage . | Treatment . |
|---|---|
| Stage IA | 30-Gy IS-RT alone |
| Early stages except for stage IA | 2 × (R-)ABVD + 20-Gy IS-RT |
| Intermediate stages | 4 × (R-)ABVD + 30-Gy IF-RT |
| Advanced stages | 6 × R-CHOP ± localized RT at 30 Gy |
ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; IF-RT, involved-field radiotherapy; IS-RT, involved-site radiotherapy; NLPHL, nodular lymphocyte-predominant Hodgkin lymphoma; R, rituximab; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; RT, radiotherapy.